The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization...

Area of Science:

• Genetics
• Gastroenterology
• Oncology

Background:

• Inflammatory bowel disease (IBD) is linked to increased malignancy risk, including lymphoma.
• Observational studies suggest a connection between IBD and malignant lymphoma, but a causal link remains unconfirmed.

Purpose of the Study:

• To investigate the potential causal relationship between inflammatory bowel disease (IBD) and malignant lymphoma using Mendelian randomization.
• To determine if specific types of IBD, Crohn's disease and ulcerative colitis, have a causal effect on diffuse large B-cell lymphoma (DLBCL).

Main Methods:

• Utilized summary data from genome-wide association studies (GWAS) for IBD and lymphoma.
• Selected single-nucleotide polymorphisms (SNPs) as genetic instrumental variables (IVs) meeting stringent statistical criteria.
• Performed Mendelian randomization (MR) analysis with sensitivity tests including Cochran's Q, MR-Egger intercept, and leave-one-out analyses to assess pleiotropy.

Main Results:

• Mendelian randomization analysis confirmed a causal effect of IBD on diffuse large B-cell lymphoma (DLBCL).
• Patients with IBD have a 28.6% increased risk of developing DLBCL (OR=1.286, P=0.009).
• Crohn's disease showed a significant causal effect on DLBCL (OR=1.218, P=0.021), while ulcerative colitis did not reach statistical significance (OR=1.206, P=0.072).

Conclusions:

• Inflammatory bowel disease (IBD) is causally associated with diffuse large B-cell lymphoma (DLBCL).
• Crohn's disease, specifically, demonstrates a causal role in the development of DLBCL.
• Further research is required to understand the underlying biological mechanisms driving this causal association.